Welcome > Support > Reference Treatises  
 
 
E
 
Read
Writer Panagene     (Date : 2016-07-13 09:39:53)
Subject [Scientific publications] [2014]Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.
Content

J Surg Oncol. 2014 Sep;110(3):245-51. doi: 10.1002/jso.23646. Epub 2014 May 29.

Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage.

Kim TJ1Park CKYeo CDPark KRhee CKKim JKim SJLee SHLee KYYoon HK.

Author information

Abstract

BACKGROUND:

Simultaneous genotyping has advantages in turnaround time and detecting the real mutational prevalence in unresectable non-small-cell lung cancer (NSCLC), a group not previously genetically characterized.

METHODS:

We developed simultaneous panel of screening EGFR and KRAS mutations by direct sequencing or PNA clamping, and ALK rearrangement by fluorescent in situ hybridization (FISH) in multicenter manner.

RESULTS:

Of 510 NSCLC Korean patients, simultaneous genotyping identified mutations of EGFR (29.0%) and KRAS (8.6%) and rearrangement of ALK (9.2%). Seven patients had overlaps in mutations. Although several well-known associations between genotypes and clinical characteristics were identified, we found no relationship between ALK rearrangement and sex or smoking history. Unlike the other genotype mutations, ALK rearrangement was associated with advanced disease. Among the ALK-negative group, patients with 10-15% of ALK FISH split shared characteristics, such as younger age and advanced stage disease, more with the ALK-positive group (>15% ALK FISH split) than <10% ALK FISH split group.

CONCLUSIONS:

Simultaneous panel genotyping revealed more prevalent ALK rearrangements than reported in previous studies and their strong association with advanced stage irrespective of sex or smoking history. ALK rearrangement seems to be a marker for aggressive tumor biology and should be assessed in advanced disease.

© 2014 Wiley Periodicals, Inc.


 

 No   Subject Writer File Count
   47           [Scientific publications] [2016]Comparison of EGFR .. Panagene 65535
   46           [Scientific publications] [2015]IDH Mutation Analys.. Panagene 65535
   45           [Scientific publications] [2015]Low frequency of KR.. Panagene 65535
   44           [Scientific publications] [2015]Simultaneous genoty.. Panagene 59909
¢º           [Scientific publications] [2014]Simultaneous diagno.. Panagene 60089
   42           [Scientific publications] [2014]KRAS Mutation Detec.. Panagene 59958
   41           [Scientific publications] [2013]Detection of EGFR m.. Panagene 60239
   40           [Scientific publications] [2013]Detection and compa.. Panagene 60247
   39           [Scientific publications] [2013]Detection of BRAF V.. Panagene 59940
   38           [Scientific publications] [2013]Comparison of Direc.. Panagene 59958
   37           [Scientific publications] [PNAClamp]Detection of EG.. Panagene 59931
   36           [Scientific publications] [Clamp]Rapid and Sensitiv.. panagene 60214
   35           [Scientific publications] [PNA microarray] Developm.. Panagene 59944
   34           [Scientific publications] [PANArray¢â] JHDM3A module.. Panagene 60114
   33           [Scientific publications] [PNA Chip vs DNA Chip cli.. Panagene 60691
   32           [Scientific publications] [Panagene publication] PN.. Panagene 62404
   31           [Scientific publications] [Panagene publication] PN.. panagene 60746
   30           [Scientific publications] [Panagene publication] Pe.. panagene 59979
   29           [Scientific publications] [Panagene publication] Hi.. panagene 60748
   28           [Scientific publications] [PNA]Membrane-based hybri.. Panagene 59955
 

< 1 2 3 >